BIO Ventures for Global Health (BVGH) invites investigators to submit information regarding their interests in conducting cancer clinical trials in sub-Saharan Africa.

The African Consortium for Cancer Clinical Trials (AC3T) launched by BVGH aims to foster and implement cancer clinical trials led by investigators in Africa. AC3T is designed to build clinical trial capacity and address the cancer data gap in Africa, while increasing access to prioritized cancer diagnostics, medicines, and quality treatment for African cancer patients.

AC3T will be implemented across three primary initiatives that will be conducted in parallel:

• Investigator-initiated, cancer feasibility studies will be conducted with funding from the AC3T Study Pool.

• Cancer clinical research capacities will be built and augmented at participating AAI hospitals.

• Hospitals’ cancer clinical trial capabilities will be profiled to encourage pharmaceutical and biotechnology companies to conduct cancer clinical trials at those hospitals.

The studies described must :

(1) Be conducted in Africa by an Africa-based investigator or with an Africa-based partner,

(2) Focus on one or more of the most common cancers in African populations, and

(3) Be aimed at improving African cancer patients’ health outcomes.

All interested respondents are requested to submit their information at no later than September 14, 2018, 5:00 PM Pacific Time.

For more information on BIO Ventures for Global Health visit the Official Website.